Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial | Circulation
EMPEROR-Preserved clinical trial review – All About Cardiovascular System and Disorders
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials - The Lancet
Visual Abstract | EMPEROR-Reduced - American College of Cardiology
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial | JACC: Heart Failure
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial | Circulation
Study design of the EMPEROR-reduced and EMPEROR-preserved trials.... | Download Scientific Diagram
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved | Nature Medicine
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM
EMPEROR-Preserved clinical trial review – All About Cardiovascular System and Disorders
Study design of the EMPEROR-reduced and EMPEROR-preserved trials.... | Download Scientific Diagram
Q&A on EMPEROR-Preserved With Javed Butler, MD
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved | Nature Medicine
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial | Circulation
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo ...
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
The EMPEROR-Preserved Trial: The Emperor's New Clothes? | BCS
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER | Nature Medicine
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
The EMPEROR-Preserved Trial: The Emperor's New Clothes? | BCS
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial - Journal of Cardiac Failure
